AlloVir(ALVR) - 2025 Q4 - Annual Report

Dividends and Earnings Retention - The company does not anticipate paying any cash dividends in the foreseeable future, expecting to retain future earnings to fund business growth [577]. Ownership and Control - As of December 31, 2025, executive officers, directors, and principal stockholder, Samsara LP, beneficially owned approximately 68.0% of the outstanding shares of common stock, allowing them to significantly influence shareholder decisions [591]. - Samsara LP controls approximately 56.5% of the voting power of the company's capital stock as of December 31, 2025, classifying the company as a "controlled company" under Nasdaq rules [593]. Capital Needs and Dilution - The company expects significant additional capital may be needed for planned operations, including clinical trials and expanded research and development activities [584]. - Future sales and issuances of common stock could result in additional dilution of existing stockholders' ownership and potentially cause stock prices to fall [584]. - The number of shares reserved for issuance under the 2020 Plan will increase by 5% of the total shares outstanding each January 1, which may lead to further dilution for stockholders [586]. Regulatory and Reporting Requirements - The company is subject to more stringent reporting requirements due to the SEC regulations applicable to reporting shell company business combinations following the Merger [581]. - The company is not eligible to use a Form S-3 until 12 full calendar months after the Current Report on Form 8-K following the closing of the Merger [583]. Market and Trading Challenges - The company may face challenges in developing an active trading market for its common stock, which could impair its ability to raise capital [579]. Litigation Costs - The Delaware Forum Provision and the Federal Forum Provision in the amended bylaws may impose additional litigation costs on stockholders [576]. Financial Strategy and Risks - The company has broad discretion over the use of its cash and cash equivalents, which may not yield a return on investment and could compromise growth strategy [596]. - Changes in tax laws, including the one percent excise tax on stock repurchases introduced by the IRA, could adversely affect the company's financial condition [597]. Registration Rights and Stock Price Impact - The company has entered into a registration rights agreement with investors from the 2025 Private Placement, which may lead to a decline in stock price due to potential resale of shares [590].